TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05073705

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment and personal transformation intervention
Description: The intervention to be delivered is the Empowerment and Personal Transformation (EPT) intervention. The EPT intervention is 6-session weekly intervention that will be given in groups. A closed group format of at least 8 participants will be used to maximize confidentiality and group cohesion. It involves elements of communication skills, empowerment and mindfulness, values and beliefs, trauma and healing, addresses issues of dependence and independence, and experiential therapy which addresses issues of emotional processing, resolution of conflicts from the past, and creative expression. The EPT intervention is 6-session weekly intervention that will be given in groups. Intervention content will be delivered by a degree level trained counselor at the MRRH HIV clinic following a manual.
Study: NCT06502548

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endometriosis
Description: Anatomopathology waste will be recovered, i.e. the remainder of the endometriosis lesions and the remainder of the endometrial biopsy.~A blood sample will be taken the day before surgery, as part of the treatment, for a hormonal check-up.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Tubal ligation or Hysterectomy
Description: During surgery, an endometrial biopsy will be taken for research purposes. A blood sample will be taken the day before surgery, as part of the treatment, for a hormonal check-up.
Study: NCT05514366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modifying EIP under a tOLA before pneumoperitoneum
Description: Phase 1:~Moment (M) 1) Standard PPV and an initial EIP of 10%~M 2) ARM with titration of optimal PEEP (PEEPop) on a decremental PEEP trial, followed by a new ARM and setting a tailored open-lung PEEP (tOL-PEEP), that 2 cm H2O higher than PEEPop~M 3) Incremental modification of the EIP in steps of 10% (from 10 to 40%)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modifying EIP under a tOLA with pneumoperitoneum
Description: Phase 2:~M 4) The investigators will apply the EIP that guarantees the lowest Pdriv~M 5) After applying pneumoperitoneum and trendelenburg~M 6) Atelectasis test (see below)~M 7) M 7a) In case of atelectasis test = negative: the investigators will modify the EIP in incremental or decremental steps of 10% M 7b) In case of atelectasis test=positive: ARM~M 8) In those cases recruited (M 7b), modify the EIP (as in M 7a)~Once the EIP that guarantees the best ventilation conditions has been stablished based on the lowest Pdriv (and higher Crs), the investigators will maintain these conditions until the end of surgery, with periodic evaluation of the pulmonary collapse by means of the atelectasis test (see below) performed every 40 minutes or regardless of time if an oxygen saturation by pulse oximetry (SpO2) \< 97% is detected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atelectasis test
Description: It is performed during mechanical ventilation, due to suspicion of alveolar collapse. Alveolar collapse will be suspected on observation of a reduction in Crs \> 10% over post-recruitment values. In these cases the atelectasis test will be performed, consisting of a reduction in FiO2 to 0.21, maintaining this FiO2 for 5 minutes. If lung collapse is \>10%, a fall in SpO2 below 97% will be expected (positive atelectasis test), in which case, an ARM and a PEEPop titration test will be performed.
Study: NCT06482164

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Dry Eye Disease
Description: Corneal sensitivity in patients who also have dry eye.
Study: NCT04844463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-68179280
Description: JNJ-68179280 will be administered as an oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-68179280
Description: JNJ-68179280 will be administered as an oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-68179280
Description: JNJ-68179280 will be administered as an oral capsule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as an oral capsule.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo will be administered as an oral capsule.
Study: NCT06044103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDB + PCS
Description: Pudendal nerve block (PNB) with ropivacaine AND Patient-controlled sedation with propofol by the participant
Study: NCT05552300

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAAE
Description: SAAE is a catheter-based percutaneous transluminal procedure which selectively injects ethanol into adrenal artery to ablate part of the adrenal gland for suppression of excessive aldosterone and catecholamines

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: traditional triple antihypertensive treatment
Description: irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: traditional triple antihypertensive treatment
Description: irbesartanhydrochlorothiazide 162.5 mg/d, amlodipine 5 mg/d
Study: NCT06100081

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Detection of lesions using fluorescence molecular imaging
Description: Using a fluorescence camera, lesions will be detected and biopsies will be taken to try and find cancer of unknown primary
Study: NCT05202392

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release with isometric exercises
Description: Patients in group A will receive 40 minutes of combined therapy treatment session including myofascial release of muscles with trigger point release and 5 isometric exercises of neck at alternative 3 days/week for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release with scapular stabilization exercise
Description: Patients in group B will get 40 minutes of myofascial therapy same as the first group combined with scapular stabilization exercise in 5 different positions and this treatment session will be at alternative 3 days/week for 4 weeks.
Study: NCT05297006

Intervention type: DIETARY_SUPPLEMENT
Intervention: The infants who drank milk powder were given a dietary intervention four months before
Description: The infants who eat milk powder were randomly divided into two groups: group containing new compound functional ingredients and group without new compound functional ingredients

Intervention type: DIETARY_SUPPLEMENT
Intervention: The infants who drank milk powder were given a dietary intervention four months before
Description: The infants who eat milk powder were randomly divided into two groups: group containing new compound functional ingredients and group without new compound functional ingredients
Study: NCT04162938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-Centered Electronic App
Description: The coordinator will enter lab information to generate the patient's Fibrosis-4 score for liver fibrosis staging. With the information of liver fibrosis staging and survey responses, the app will generate individualized reports of the participant's comprehensive HCV disease progression, knowledge, and level of interest in receiving HCV care. The app will then deliver a streamlined, tailored, brief education message and include information regarding services and assistance for receiving HCV care.
Study: NCT05271721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural transforaminal injection of magnesuim sulfate
Description: transforaminal fluroscopic guided

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural transforaminal injection of dexmedtemodine
Description: transforaminal fluroscopic guided

Intervention type: DRUG
Group type: OTHER
Intervention: transforaminal epidural injection of dexamethasone
Description: transforaminal fluroscopic guided
Study: NCT04220619

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tranesophageal Echocardiography
Description: RescueTEE during ACLS versus Conventional ACLS
Study: NCT04766723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT 201
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NT 201
Description: Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Study: NCT05944939

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical extraction of impacted third molar
Description: After surgical extraction of mandibular impacted teeth concentrated growth factor placed in socket closure done with help of silk 3.0 suture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical extraction of impacted third molar
Description: After surgical extraction of mandibular impacted teeth concentrated growth factor placed in socket closure done with help of silk 3.0 suture
Study: NCT05127187

Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid diagnosis test against HIV and hepatitis C and B
Description: combined Insti VIH® + Toyo VHC®, then First response Ag Hbs tested on capillary blood sample
Study: NCT05213299

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AURICULAR ACUPUNCTURE
Description: Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, the investigators use press tack needles to perform auricular acupuncture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AURICULAR ACUPUNCTURE
Description: Auricular acupuncture is a method for diagnosing and treating physical and psychosomatic dysfunctions by stimulating a specific point in the ear. To conducting this intervention, the investigators use press tack needles to perform auricular acupuncture.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: For this intervention, instead of needles, the investigators use four pieces of tape.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLACEBO
Description: For this intervention, instead of needles, the investigators use four pieces of tape.
Study: NCT06327412

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise on the treadmill
Description: According to the cardiopulmonary exercise (CPET) test, 40 minutes (5 minutes warm-up, 30 minutes exercise, 5 minutes cool-down) at an exercise intensity of 50-60% of the VO2 max (the maximum amount of oxygen that an individual can utilize during intense or maximal exercise) level recorded individually in patients, 5 days a week for 4 weeks.Both patient groups will be given lymphedema-specific remedial exercise program training. Anatolian Lymphedema Association lower extremity lymphedema exercise sheets will be delivered to the patients in writing, and training on exercise practices will be given face to face as a session by a physiotherapist at the physical therapy lymphedema outpatient clinic. Patients will be asked to perform these exercises daily as stated in the leaflet and in the number of repetitions. Patients will be given an exercise diary to ensure their compliance with exercise and will be asked to mark this form daily
Study: NCT05842551

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Prismatic adaptation and electric stimulation
Description: Combinatory effect of tEs and prismatic lenses in the experimental group and of sham stimulation and prismatic lenses in control group

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prismatic adaptation and electric stimulation
Description: Combinatory effect of tEs and prismatic lenses in the experimental group and of sham stimulation and prismatic lenses in control group
Study: NCT06416644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supera Vasculomimetic Stent
Description: Femoral-popliteal revascularization with Supera Stent
Study: NCT06327412

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Walking between 12-13 RPE (The Borg Rating of Perceived Exertion) according to the Modified Borg Scale
Description: He/she will be asked to walk 40 minutes a day, 5 days a week, for 4 weeks. Training will be given for the first session in the hospital to ensure that the patient's walking pace is between 12-13 RPE according to the Modified Borg scale.Both patient groups will be given lymphedema-specific remedial exercise program training. Anatolian Lymphedema Association lower extremity lymphedema exercise sheets will be delivered to the patients in writing, and training on exercise practices will be given face to face as a session by a physiotherapist at the physical therapy lymphedema outpatient clinic. Patients will be asked to perform these exercises daily as stated in the leaflet and in the number of repetitions. Patients will be given an exercise diary to ensure their compliance with exercise and will be asked to mark this form daily.Treatment compliance will be increased by making weekly phone calls to patients in order to increase treatment compliance and evaluate compliance.
Study: NCT05030844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMB model based Diabetes Education and Motivational Interviewing
Description: IMB model-based interventions were applied to the intervention group for 3 month. For the information component of the IMB model, diabetes education consisting of four sessions was given in groups of five in the first two weeks. Each patient was given a Diabetes Management Education Booklet prepared by the researchers. For the motivation component of the IMB model, total 5 sessions 30-minute motivational interview was made with individual Whatsapp calls once every two weeks starting from the third week.
Study: NCT05571410

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HTN Chat bot
Description: Remote monitoring via automated messaging program
Study: NCT05120076

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 Mg/mL Injectable Solution
Description: s. arm/group description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: s. arm/group description
Study: NCT06420531

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Human milk
Description: maternal breastmilk or donor breastmilk

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human milk
Description: maternal breastmilk or donor breastmilk
Study: NCT00240799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen extended release

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT05447572

Intervention type: OTHER
Intervention: FIT + FC
Description: FIT + FC
Study: NCT06238570

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gavi, Merck® (automated vitrification instrument)
Description: This instrument recently appeared on the market and demonstrated a high effectiveness in terms of processing time and reproducibility for embryo vitrification. To date, no study has analyzed the efficiency of this automated vitrification instrument on oocyte vitrification.~The oocytes will be stored in closed cassettes in liquid nitrogen

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vitrolife system
Description: The oocytes vitrification will be carried out by an authorized technician according to the manual protocol validated and used routinely.
Study: NCT03678428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150 mg/m2 IV over 90 minutes on Day 1 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin HAI
Description: Oxaliplatin 85 mg/m2 over 3 hours will be administered through the HAI pump on day 1. Oxaliplatin 85 mg/m2 IV over 3 hours on day 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Description: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin 200mg/m2 IV on Day 1 and 15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU 2400mg/m2 CIV in 46h on Day 1 and 15.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2 IV over 3 hours on Day1 and 15.
Study: NCT06352684

Intervention type: DEVICE
Intervention: CadAI-B for Breast
Description: CadAI-B for Breast is designed to assist healthcare professionals in lesion detection and differential diagnosis during breast US examinations.

Intervention type: DEVICE
Intervention: CadAI-B for Breast
Description: CadAI-B for Breast is designed to assist healthcare professionals in lesion detection and differential diagnosis during breast US examinations.

Intervention type: DEVICE
Intervention: CadAI-B for Breast
Description: CadAI-B for Breast is designed to assist healthcare professionals in lesion detection and differential diagnosis during breast US examinations.
Study: NCT03537495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Overall, there is an urgent need for improvement of TBM treatment. LInezolid is known to be well-penetrated to blood brain barrier. A combination of high-dose rifampicin and linezolid as an intensified add-on therapy in the management of TB meningitis has never been studied.~The goal is to assess the most appropriate dose of linezolid for larger follow-up studies and to evaluate the feasibility of a linezolid-containing TBM regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: Overall, there is an urgent need for improvement of TBM treatment. LInezolid is known to be well-penetrated to blood brain barrier. A combination of high-dose rifampicin and linezolid as an intensified add-on therapy in the management of TB meningitis has never been studied.~The goal is to assess the most appropriate dose of linezolid for larger follow-up studies and to evaluate the feasibility of a linezolid-containing TBM regimen.
Study: NCT06404437

Intervention type: DIAGNOSTIC_TEST
Intervention: Auscultation
Description: Auscultation at five auscultation points using a digital stethoscope and a smartphone
Study: NCT06194552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTRX-07
Description: Investigational orally administered CB2 agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTRX-07
Description: Investigational orally administered CB2 agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTRX-07
Description: Investigational orally administered CB2 agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTRX-07
Description: Investigational orally administered CB2 agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTRX-07
Description: Investigational orally administered CB2 agonist

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo administered orally
Study: NCT05723159

Intervention type: DEVICE
Intervention: Clinical Validation of the Hyfe Cough Monitoring System
Description: The subjects will be instructed to not turn off either watch for the duration of the 24 hours. In addition, participants will be instructed to avoid environments with active coughers and to inform others in their environment that sound is being recorded. Additionally, participants will be told to avoid getting the watches wet. Participants will be instructed to charge the watches on a nightstand next to the bed while they sleep using the provided watch chargers. At the end of the 24-hour period, participants will be instructed to turn off and remove the watches. Additionally, participants will be given a printed Hyfe diary to write down the exact time when the device was turned on/off and any times the watch was not being worn. The devices will be returned to the researchers once the recording period is complete.

Intervention type: DEVICE
Intervention: Clinical Validation of the Hyfe Cough Monitoring System
Description: The subjects will be instructed to not turn off either watch for the duration of the 24 hours. In addition, participants will be instructed to avoid environments with active coughers and to inform others in their environment that sound is being recorded. Additionally, participants will be told to avoid getting the watches wet. Participants will be instructed to charge the watches on a nightstand next to the bed while they sleep using the provided watch chargers. At the end of the 24-hour period, participants will be instructed to turn off and remove the watches. Additionally, participants will be given a printed Hyfe diary to write down the exact time when the device was turned on/off and any times the watch was not being worn. The devices will be returned to the researchers once the recording period is complete.

Intervention type: DEVICE
Intervention: Clinical Validation of the Hyfe Cough Monitoring System
Description: The subjects will be instructed to not turn off either watch for the duration of the 24 hours. In addition, participants will be instructed to avoid environments with active coughers and to inform others in their environment that sound is being recorded. Additionally, participants will be told to avoid getting the watches wet. Participants will be instructed to charge the watches on a nightstand next to the bed while they sleep using the provided watch chargers. At the end of the 24-hour period, participants will be instructed to turn off and remove the watches. Additionally, participants will be given a printed Hyfe diary to write down the exact time when the device was turned on/off and any times the watch was not being worn. The devices will be returned to the researchers once the recording period is complete.
Study: NCT05916898

Intervention type: DEVICE
Intervention: PCI with support of Shockwave Intravascular Lithotripsy
Description: Coronary artery angioplasty of the primary lesion or optimization of the previously implanted stent with the support of Shockwave Intravascular Lithotripsy device
Study: NCT06308471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby massage was applied to the intervention group (n=20) of the study
Description: The application was applied for 15 minutes every day for ten days, and oral feeding trials were video recorded. Feeding videos were evaluated by expert neonatal nurses using The Oral Feeding Scale without knowing the application group of the babies.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral stimulation
Description: The application was applied for 15 minutes every day for ten days, and oral feeding trials were video recorded. Feeding videos were evaluated by expert neonatal nurses using The Oral Feeding Scale without knowing the application group of the babies.